TLDR
FDA Commissioner Marty McCary details 42 major reforms in his first 10 months, including cutting pivotal trial requirements from two to one, eliminating animal testing mandates, launching a 55-day approval pilot, and overhauling food guidance to prioritize protein over refined carbs. He emphasizes modernizing the FDA with AI, Bayesian statistics, and continuous trials to compete with China's speed, while pursuing Most Favored Nation drug pricing, accelerating biosimilars, and shifting more drugs OTC. McCary critiques institutional dogma in nutrition, vaccines, and chronic disease research, advocating for root-cause science over paternalistic mandates. He also discusses autism's potential microbiome links, NIH funding reallocation, and a vision for cures in type 1 diabetes, ALS, and PTSD. The conversation reveals deep structural inefficiencies (e.g., 2,000 HR staff for 20,000 employees) and a cultural shift toward speed, transparency, and humility. McCary frames reform as a moral imperative driven by bedside experience, not politics. The episode captures a regulator attempting to rewire a massive bureaucracy from within. The stakes are framed as life-and-death for patients waiting on delayed cures. The tone is urgent, data-driven, and unapologetically disruptive. The interview is a rare inside look at FDA decision-making and the philosophy driving its current transformation.
For you
PRO members can sign in and request more information — or their own version of this digest, tuned to what they care about.
Sign in to unlockSurprising Insights
FDA had 2,000 HR and 1,500 IT staff for 20,000 employees; no scientific reviewers laid off in restructuring — cuts targeted duplicative administrative roles.
144 chimpanzees required per monoclonal antibody application; aspirin might not pass old animal testing rules (two-species requirement) because drugs safe in animals often fail in humans (90% failure rate).
14% of NIH grants (~$40B budget) went to DEI research describing health disparities rather than addressing root causes; NIH culture myopically focused on genetic solutions for 50 years.
Fruit Loops made different formulations for Canada (no petroleum dyes) vs. US; 1,000+ chemicals in US food supply banned elsewhere.
60% of antibiotics prescribed in US are unnecessary; opioid crisis could have been caught years earlier with big data surveillance — Vioxx killed ~38,000 before detection.
Minnesota Heart Study (9,000 people) showed low-fat diet increased heart attacks; results suppressed for 16 years because 'they didn't turn out the way we expected.'
FDA sent 0 enforcement letters on misleading drug ads in prior year; McCary sent 1,500 including 100+ cease-and-desist in 10 months.
Most great scientists start as heretics — H. pylori ulcer discovery was rejected, then won Nobel Prize; similar suppression seen in peanut allergy guidance (avoid until 3) which caused epidemic.
Key takeaways
FDA implemented 42 major reforms in 10 months: reduced pivotal trials from two to one, eliminated chimp studies for monoclonal antibodies, launched pilot for approval decisions in weeks (first at 55 days), and made rejection letters public for accountability.
Restructuring to compete with China: centralizing IRBs and hospital contracting, using AI to cut application completeness review from 60 days to 1 day, adopting Bayesian statistics for real-time trial monitoring, and hiring 1,050 new scientists for accelerated pathways.
Food policy overhaul: flipped food pyramid to prioritize protein over refined carbs, banned 9 petroleum-based dyes, targeted ultra-processed foods as driver of childhood chronic disease (38% of kids have prediabetes/diabetes), and launched realfood.gov.
Vaccine schedule reform: identified 38 'core essential' doses (down from 72) aligned with 20-country consensus to rebuild trust; questioned hepatitis B at birth for negative mothers; all vaccines still recommended but hierarchy introduced.
Drug pricing strategy: Most Favored Nation pricing (GLP-1s from $1,300 to $149/3 months), biosimilar approval cut from 5-8 years to 2.5 years, pushing more drugs OTC to enable price transparency and bypass PBM 'shell games'.
Notable quotes
“Why does it take 10 to 12 years for a new drug to come to market? We've become so lukewarm and passive, accepting that horrible timeline that has just become the status quo.”
▸ Notable quotes · 4:46“We're going to get that down to one day. We're going to use AI.”
▸ Notable quotes · 11:21“The right to try law gives patients access to drugs... I have signed 100% of right to try requests that come across my desk.”
▸ Notable quotes · 25:25“We have failed with our food system. Look at the fact that 40% of American kids have a chronic disease.”
▸ Notable quotes · 42:21“Most great scientists start out as heretics.”
▸ Notable quotes · 59:10“We have got to move at the speed that my patients demanded, not at government speed.”
▸ Notable quotes · 89:04Chapters
0:00 — Introduction & Background: Marty McCary, FDA Commissioner, discusses his path to the role via public health research, price transparency work, and relationships from first Trump administration.
2:00 — COVID Lessons & FDA Culture Change: Critiques pandemic-era dogma: cloth masks on toddlers, vaccine mandates for young people, ignoring natural immunity, school closures. Vows to rebuild trust by challenging sacred cows.
7:00 — Restructuring & Staffing: Consolidated 2,000 HR and 1,500 IT roles; no scientific reviewers laid off. Centralized siloed centers. Culture shift: priority from 'fighting misinformation' to 'delivering cures faster.' Turnover at baseline 5-7%.
13:00 — China Competition & Phase 1 Acceleration: US losing biotech race to China (Phase 1 in 4 weeks vs years). Priorities: centralized IRBs, streamlined hospital contracting, AI for 1-day application review, modernizing IND process.
19:00 — Congressional Role & FDA Performance Metrics: Wants higher user fees for overseas Phase 1s (America First). Not waiting for Congress. Hit 100% user fee target dates in 2025; review decisions align with primary teams; record approvals in cell/gene therapy.
23:00 — Clinical Trial Phases & Reform: Explains Phase 1-3. Announced shift from two pivotal trials to one (saves $100-300M). Eliminating animal testing via computational modeling and organ-on-chip. Chimpanzee studies for monoclonals removed.
29:00 — Computational Modeling & Animal Testing: Animal studies mislead: 90% of drugs passing animals fail in humans. Computational modeling and organ-on-chip are superior. Modernizing pre-IND requirements.
35:00 — Continuous Trials & Bayesian Statistics: Vision for continuous trials with endpoints in cloud. Announced Bayesian statistics for real-time safety/efficacy calls. Post-market surveillance via big data to catch signals like Vioxx/opioids early.
40:00 — Right to Try & Cell/Gene Therapy: Signed 100% of Right-to-Try requests. Announced flexible manufacturing for cell/gene therapies (bespoke treatments like baby KJ's gene editing). Plausible mechanism pathway for ultra-rare diseases.
46:00 — Food Pyramid & Nutrition Science: Flipped pyramid to prioritize protein. 38% kids prediabetic/diabetic; 60-70% calories from refined carbs. Nutrition science corrupted by industry/academia. Dogma on saturated fat, peanut avoidance caused harm.
55:00 — GLP-1s & Obesity: Food system failed; GLP-1s mimic natural hormone, reduce insulin resistance/inflammation. Benefits beyond weight: cardiac, addiction, cancer. But root cause is ultra-processed food, not willpower.
60:00 — NIH Funding & Root Cause Research: No NIH/Medicaid cuts; reallocating from genetic focus to food-as-medicine, microbiome, environmental exposures. 14% grants to DEI describing disparities. Jay Bhattacharya reforming NIH.
69:00 — Vaccine Schedule Reform: US outlier with 72 doses (0-18). Reviewed 20 countries: consensus on 38 core essential doses. Hep B at birth for negative mothers questioned. Goal: rebuild trust, increase uptake.
80:00 — State Pushback & Polarization: California setting own schedule. Toxic polarization in medicine. Core list by credentialed scientists (Hogue, Bhattacharya, Oz, McCary). Absolutism hurts trust; need humility (e.g., mammogram vs ultrasound).
85:00 — Drug Pricing & Most Favored Nation: US pays 3x other countries. Trump mandate: Most Favored Nation pricing. GLP-1s to $149/3 months. Other nations must pay fair share of R&D (US funds 60%).
92:00 — Biosimilars & OTC Switch: Biologics drive spending growth. Biosimilar approval cut from 5-8 years/$300M to 2.5 years. Floodgates opening. Pushing more drugs OTC: if no abuse potential, safe, no lab monitoring needed — enables price transparency, bypasses PBMs.
98:00 — Pharma Advertising Enforcement: Prior admin sent 0 enforcement letters on ads. McCary sent 1,500 including 100+ cease-and-desist. Closing 'adequate provision' loophole. Wants pharma to spend marketing budget on lowering prices.
103:00 — AI Regulation & Wearables: New guidance: consumer lane for wearables (heart rate, glucose). Medical-grade claims require FDA validation. Predictability for developers/investors. Can't regulate all AI info like Google search.
106:00 — Alternative Proteins & GRAS: GRAS loophole abused for engineered chemicals. Closing it. 1,000+ US chemicals banned elsewhere. Cellular meat/seafood evolving; FDA registers but states regulate sales. Supports protein innovation.
112:00 — Autism & Microbiome: 1 in 12 boys in CA diagnosed. Hypotheses: autoimmune blocking folate receptors (leucovorin bypass), microbiome disruption (C-sections, antibiotics, formula). JAMA trial: protease improved autism symptoms. Drugging kids instead of fixing root causes.
120:00 — Chronic Disease Root Causes: Most chronic disease from insulin resistance and general inflammation. Saturated fat not the driver (Minnesota Heart Study suppressed 16 years). Denatured proteins, non-natural chemicals cause low-grade inflammation.
126:00 — Future Frontiers & Optimism: Goals: cure/type 1 diabetes treatment, ALS therapy, tumor-melting cancer drugs (PD-1/KRAS), universal flu shot, PTSD treatment for veterans (7,000+ suicides/year). FDA as referee; priority vouchers for breakthroughs (congenital deafness gene therapy, myeloma 3x better).
Speakers
Marty McCary — FDA Commissioner, surgeon, public health researcher, former Johns Hopkins faculty
Dave — Host (likely Dave Friedberg), investor, All In podcast co-host